Ligand ID: 3WF


Drugbank ID:
DB00977
(Ethinyl Estradiol)



Indication:
For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.


Get human targets for 3WF in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND '3WF'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.


DrReposER ID / Desc. Hit
PDBID
Hit
Macromolecule
Res.
Matches
View Interface RMSD Seq.
Identity (%)
HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
1z1i 3C-LIKE PROTEINASE
(SARSr-CoV)
5 / 12
ASP A  56
SER A  65
PHE A  66
LEU A  58
ILE A  59
1.43A19.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2fav REPLICASE
POLYPROTEIN 1AB
(PP1AB) (ORF1AB)
(SARSr-CoV)
5 / 12
LEU C  54
LEU C  89
SER C  30
LEU C 124
ILE C  36
1.54A23.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2fav REPLICASE
POLYPROTEIN 1AB
(PP1AB) (ORF1AB)
(SARSr-CoV)
5 / 12
LEU C  54
LEU C  89
SER C  30
LEU C 124
ILE C  36
1.48A23.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)
5 / 12
LEU C 153
LEU C 114
HIS C 172
LEU C 173
ILE C 152
1.22A21.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)
5 / 12
LEU C 153
LEU C 114
HIS C 172
LEU C 173
ILE C 152
1.23A21.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)
5 / 12
ASP A 282
LEU A 245
ARG A 257
LEU A 254
ILE A 280
1.34A19.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)
5 / 12
ASP A 282
LEU A 245
ARG A 257
LEU A 254
ILE A 280
1.32A19.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2k87 NSP3 OF REPLICASE
POLYPROTEIN 1A
(SARSr)
5 / 12
ASP A  21
SER A  47
LEU A  25
ARG A  48
LEU A 108
1.38A15.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2kys NSP7
(SARSr-CoV)
5 / 12
LEU A  57
SER A  56
LEU A  73
MET A  77
ILE A  70
1.44A15.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2kys NSP7
(SARSr-CoV)
5 / 12
LEU A  57
SER A  56
LEU A  73
MET A  77
ILE A  70
1.42A15.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2qcy 3C-LIKE PROTEINASE
(SARSr-CoV)
5 / 12
ASP A  56
SER A  65
PHE A  66
LEU A  58
ILE A  59
1.45A19.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)
5 / 12
ASP A 282
LEU A 245
ARG A 257
LEU A 254
ILE A 280
1.25A22.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)
5 / 12
ASP A 282
LEU A 245
ARG A 257
LEU A 254
ILE A 280
1.29A22.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)
5 / 12
LEU A 126
LEU A  85
SER A 105
PHE A 103
ILE A 128
1.28A20.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)
5 / 12
LEU A 126
LEU A  85
SER A 105
PHE A 103
ILE A 128
1.31A20.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2xyv PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)
5 / 12
LEU A 126
LEU A  85
SER A 105
PHE A 103
ILE A 128
1.27A20.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
2xyv PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)
5 / 12
LEU A 126
LEU A  85
SER A 105
PHE A 103
ILE A 128
1.30A20.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
3bgf F26G19 FAB
(Mus
musculus)
5 / 12
LEU C  73
SER C  20
LEU C  47
LEU C  54
ILE C  48
1.35A21.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
3bgf F26G19 FAB
(Mus
musculus)
5 / 12
LEU C  73
SER C  20
LEU C  47
LEU C  54
ILE C  48
1.38A21.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
3e9s NSP3
(SARSr-CoV)
5 / 12
LEU A 153
LEU A 114
HIS A 172
LEU A 173
ILE A 152
1.32A22.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
3e9s NSP3
(SARSr-CoV)
5 / 12
LEU A 153
LEU A 114
HIS A 172
LEU A 173
ILE A 152
1.31A22.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
3ebn REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)
5 / 12
LEU D 268
LEU B 205
SER D 254
ARG D 222
LEU D 262
1.54A17.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
3ebn REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)
5 / 12
LEU D 268
LEU B 205
SER D 254
ARG D 222
LEU D 262
1.52A17.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
3ee7 REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)
5 / 12
LEU A   4
SER A   5
LEU A  42
MET A 101
SER A 105
1.54A15.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
3f9e 3C-LIKE PROTEINASE
(SARSr-CoV)
5 / 12
ASP A  56
SER A  65
PHE A  66
LEU A  58
ILE A  59
1.40A19.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
3f9e 3C-LIKE PROTEINASE
(SARSr-CoV)
5 / 12
ASP A  56
SER A  65
PHE A  66
LEU A  58
ILE A  59
1.39A19.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
3iwm 3C-LIKE PROTEINASE
(SARSr-CoV)
5 / 12
ASP B 216
LEU B 208
MET D 264
PHE D 223
ILE D 281
1.39A19.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)
5 / 12
LEU A 126
LEU A  85
SER A 105
PHE A 103
ILE A 128
1.40A22.01
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)
5 / 12
LEU A 126
LEU A  85
SER A 105
PHE A 103
ILE A 128
1.37A22.01
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)
5 / 12
LEU A 529
SER A 547
PHE A 438
LEU A 410
ILE A 407
1.42A19.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)
5 / 12
LEU A 529
SER A 547
PHE A 438
LEU A 410
ILE A 407
1.40A19.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
4m0w REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)
5 / 12
LEU A 153
LEU A 114
HIS A 172
LEU A 173
ILE A 152
1.32A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
4m0w REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)
5 / 12
LEU A 153
LEU A 114
HIS A 172
LEU A 173
ILE A 152
1.33A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
4m0w UBIQUITIN
(Bos
taurus)
5 / 12
ASP B  21
LEU B  56
LEU B  67
LEU B  15
ILE B   3
1.38A12.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
4ovz PAPAIN-LIKE
PROTEINASE
(SARS-COV
Urbani)
5 / 12
LEU B 153
LEU B 114
HIS B 172
LEU B 173
ILE B 152
1.30A22.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
4ovz PAPAIN-LIKE
PROTEINASE
(SARS-COV
Urbani)
5 / 12
LEU B 153
LEU B 114
HIS B 172
LEU B 173
ILE B 152
1.29A22.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5b6o 3C-LIKE PROTEINASE
(SARSr-CoV)
5 / 12
LEU A 271
LEU A 287
SER B 284
ARG A 279
ILE A 281
1.39A18.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5b6o 3C-LIKE PROTEINASE
(SARSr-CoV)
5 / 12
LEU A 271
LEU A 287
SER B 284
ARG A 279
ILE A 281
1.42A18.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5c5o 3C-LIKE PROTEINASE
(SARSr-CoV)
5 / 12
LEU A 271
LEU A 287
SER B 284
ARG A 279
ILE A 281
1.45A19.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5c5o 3C-LIKE PROTEINASE
(SARSr-CoV)
5 / 12
LEU A 271
LEU A 287
SER B 284
ARG A 279
ILE A 281
1.41A19.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5e6j REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)
5 / 12
LEU A 153
LEU A 114
HIS A 172
LEU A 173
ILE A 152
1.30A21.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5e6j POLYUBIQUITIN-B
(synthetic
construct)
5 / 12
ASP F  21
LEU F  56
LEU F  67
LEU F  15
ILE F   3
1.36A13.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5e6j UBIQUITIN
(synthetic
construct)
5 / 12
ASP E  21
LEU E  56
LEU E  67
LEU E  15
ILE E   3
1.27A12.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5e6j REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)
5 / 12
LEU A 153
LEU A 114
HIS A 172
LEU A 173
ILE A 152
1.30A21.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5e6j POLYUBIQUITIN-B
(synthetic
construct)
5 / 12
ASP F  21
LEU F  56
LEU F  67
LEU F  15
ILE F   3
1.36A13.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5tl7 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)
5 / 12
LEU B 153
LEU B 114
HIS B 172
LEU B 173
ILE B 152
1.29A21.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5tl7 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)
5 / 12
LEU B 153
LEU B 114
HIS B 172
LEU B 173
ILE B 152
1.29A21.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)
5 / 12
LEU B 959
SER B 957
LEU B 963
SER A 370
ILE B 975
1.26A13.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)
5 / 12
LEU B 959
SER B 957
LEU B 963
SER A 370
ILE B 975
1.29A13.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)
5 / 12
LEU A 983
SER A 985
LEU A 735
SER A 728
ILE A 979
1.51A14.61
LEU  A 983 ( 0.6A)
SER  A 985 ( 0.0A)
LEU  A 735 ( 0.6A)
SER  A 728 ( 0.0A)
ILE  A 979 ( 0.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)
5 / 12
LEU B 983
SER B 985
LEU B 735
SER B 728
ILE B 979
1.53A14.61
LEU  B 983 ( 0.6A)
SER  B 985 ( 0.0A)
LEU  B 735 ( 0.6A)
SER  B 728 ( 0.0A)
ILE  B 979 ( 0.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5y3q REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)
5 / 12
LEU A 153
LEU A 114
HIS A 172
LEU A 173
ILE A 152
1.31A21.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5y3q REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)
5 / 12
LEU A 153
LEU A 114
HIS A 172
LEU A 173
ILE A 152
1.31A21.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5zvm PAN-COV INHIBITORY
PEPTIDE EK1
SPIKE GLYCOPROTEIN
(SARSr-CoV;
synthetic
construct)
5 / 12
ASP c   9
LEU c   8
LEU A 944
PHE c  15
ILE c  11
1.55A12.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
5zvm PAN-COV INHIBITORY
PEPTIDE EK1
SPIKE GLYCOPROTEIN
(SARSr-CoV;
synthetic
construct)
5 / 12
ASP c   9
LEU c   8
LEU A 944
PHE c  15
ILE c  11
1.54A12.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)
5 / 12
ASP C 961
LEU C 978
SER C 728
LEU C 963
ILE C 962
1.52A14.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)
5 / 12
LEU B 983
SER B 985
LEU B 735
SER B 728
ILE B 979
1.53A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)
5 / 12
LEU B 983
SER B 985
LEU B 735
SER B 728
ILE B 979
1.50A14.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)
5 / 12
ASP A 518
SER A 516
ARG A 315
LEU A 538
ILE A 520
1.40A14.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)
5 / 12
ASP A 518
SER A 516
ARG A 315
LEU A 538
ILE A 520
1.36A14.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6lxt SPIKE PROTEIN S2
(SARS-CoV-2)
5 / 12
LEU D 977
SER D 975
LEU E 977
SER F 975
ILE E 973
1.21A18.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6lxt SPIKE PROTEIN S2
(SARS-CoV-2)
5 / 12
LEU D 977
SER D 975
LEU E 977
SER F 975
ILE E 973
1.20A18.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)
6 / 12
ASP A 486
LEU A 482
SER A 483
PHE A 420
LEU A  52
ILE A 132
1.71A19.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)
6 / 12
ASP A 486
LEU A 482
SER A 483
PHE A 420
LEU A  52
ILE A 132
1.76A19.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m1d ACE2
(Homo
sapiens)
5 / 12
LEU B 554
LEU B 558
PHE B 327
HIS B 373
MET B 323
1.50A18.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m1d ACE2
(Homo
sapiens)
5 / 12
LEU B 554
LEU B 558
PHE B 327
HIS B 373
MET B 323
1.48A18.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP12
(SARS-CoV-2)
5 / 12
LEU A 869
SER A 434
HIS A 439
ARG A 836
LEU A 838
1.79A15.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP12
(SARS-CoV-2)
5 / 12
LEU A 212
LEU A 178
PHE A 165
LEU A 142
ILE A 145
1.42A15.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP12
NSP8
(SARS-CoV-2)
5 / 12
LEU B 103
LEU B  98
MET A 380
LEU B 117
ILE B 120
1.72A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP7
(SARS-CoV-2)
5 / 12
ASP C  38
LEU C  55
SER C  15
LEU C  40
ILE C  39
1.73A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP12
NSP8
(SARS-CoV-2)
5 / 12
LEU A 271
LEU A 270
SER B 151
LEU B 122
ILE B 119
1.79A15.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP12
(SARS-CoV-2)
5 / 12
LEU A 131
LEU A 127
ARG A 132
LEU A 241
ILE A 244
1.48A15.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP12
(SARS-CoV-2)
5 / 12
LEU A 212
LEU A 178
PHE A 165
LEU A 142
ILE A 145
1.40A15.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP7
NSP8
(SARS-CoV-2)
5 / 12
LEU D  91
LEU C  56
MET C  52
HIS C  36
LEU C  17
1.66A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP12
(SARS-CoV-2)
5 / 12
SER A 814
LEU A 869
HIS A 439
ARG A 836
LEU A 838
1.73A15.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP12
(SARS-CoV-2)
5 / 12
ASP A 126
LEU A 178
PHE A 165
LEU A 142
ILE A 145
1.22A15.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP12
NSP8
(SARS-CoV-2)
5 / 12
LEU B 103
LEU B  98
MET A 380
LEU B 117
ILE B 120
1.73A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP12
(SARS-CoV-2)
5 / 12
ASP A 126
LEU A 178
PHE A 165
LEU A 142
ILE A 145
1.23A15.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP12
(SARS-CoV-2)
5 / 12
ASP A 304
LEU A 636
PHE A 283
ARG A 305
ILE A 307
1.69A15.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP12
(SARS-CoV-2)
5 / 12
ASP A 304
LEU A 636
PHE A 283
ARG A 305
ILE A 307
1.72A15.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP7
NSP8
(SARS-CoV-2)
5 / 12
LEU D  91
LEU C  56
MET C  52
HIS C  36
LEU C  17
1.71A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6m71 NSP7
(SARS-CoV-2)
5 / 12
ASP C  38
LEU C  55
SER C  15
LEU C  40
ILE C  39
1.69A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)
5 / 12
LEU C 983
SER C 985
LEU C 735
SER C 728
ILE C 979
1.53A13.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)
5 / 12
LEU C 983
SER C 985
LEU C 735
SER C 728
ILE C 979
1.53A13.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6nus NSP12
(SARSr-CoV)
6 / 12
ASP A 126
LEU A 212
LEU A 178
PHE A 165
LEU A 142
ILE A 145
1.36A16.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6nus NSP12
(SARSr-CoV)
6 / 12
ASP A 126
LEU A 212
LEU A 178
PHE A 165
LEU A 142
ILE A 145
1.38A16.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6vxs NSP3
(SARS-CoV-2)
5 / 12
ASP A  66
LEU A  75
PHE A 132
HIS A  45
ILE A  69
1.77A
None
SO4  A 201 (-4.1A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6vxs NSP3
(SARS-CoV-2)
5 / 12
ASP B  66
LEU B  75
PHE B 132
HIS B  45
ILE B  69
1.75A
None
SO4  B 201 ( 4.4A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6vxs NSP3
(SARS-CoV-2)
5 / 12
ASP A  66
LEU A  75
PHE A 132
HIS A  45
ILE A  69
1.75A
None
SO4  A 201 (-4.1A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6vxs NSP3
(SARS-CoV-2)
5 / 12
ASP B  66
LEU B  75
PHE B 132
HIS B  45
ILE B  69
1.72A
None
SO4  B 201 ( 4.4A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)
5 / 12
LEU C 977
SER C 975
LEU C 981
SER B 383
ILE C 993
1.47A12.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)
5 / 12
LEU A 977
SER A 975
LEU A 981
SER C 383
ILE A 993
1.42A12.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)
5 / 12
LEU A 977
SER A 975
LEU A 981
SER C 383
ILE A 993
1.45A12.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)
5 / 12
ASP A 283
LEU A 246
ARG A 258
LEU A 255
ILE A 281
1.36A20.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)
5 / 12
ASP B 283
LEU B 246
ARG B 258
LEU B 255
ILE B 281
1.36A20.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w4h NSP16
(SARS-CoV-2)
5 / 12
LEU A6924
LEU A6883
SER A6903
PHE A6901
ILE A6926
1.33A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w4h NSP16
(SARS-CoV-2)
5 / 12
LEU A6924
LEU A6883
SER A6903
PHE A6901
ILE A6926
1.37A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A6848
LEU A6883
LEU A6924
ILE A6926
MET A6863
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A6924
LEU A6883
SER A6903
PHE A6901
ILE A6926
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A6924
LEU A6883
SER A6903
PHE A6901
ILE A6926
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A7070
SER A7071
LEU A6961
LEU A7060
ILE A7065
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A7070
SER A7071
LEU A6961
LEU A7060
ILE A7065
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A6848
LEU A6883
LEU A6924
ILE A6926
MET A6863
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A7078
PHE A6985
ARG A7081
LEU A6961
ILE A7080
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A7078
PHE A6985
ARG A7081
LEU A6961
ILE A7080
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w6y NSP3
(SARS-CoV-2)
5 / 12
SER B   7
LEU A 153
SER A 139
LEU A 164
ILE A  18
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w6y NSP3
(SARS-CoV-2)
5 / 12
LEU B 164
LEU B 140
PHE B 116
LEU B 153
ILE B  18
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w6y NSP3
(SARS-CoV-2)
5 / 12
SER B   7
LEU A 153
SER A 139
LEU A 164
ILE A  18
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w6y NSP3
(SARS-CoV-2)
5 / 12
LEU A 164
LEU A 140
PHE A 116
LEU A 153
ILE A  18
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU C7070
SER C7071
LEU C6961
LEU C7060
ILE C7065
1.59A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU A6848
LEU A6883
LEU A6924
ILE A6926
MET A6863
1.71A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU A7078
PHE A6985
ARG A7081
LEU A6961
ILE A7080
1.57A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU A6924
LEU A6883
SER A6903
PHE A6901
ILE A6926
1.35A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU C6848
LEU C6883
LEU C6924
ILE C6926
MET C6863
1.72A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU A7070
SER A7071
LEU A6961
LEU A7060
ILE A7065
1.61A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU A6924
LEU A6883
SER A6903
PHE A6901
ILE A6926
1.31A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU A7078
PHE A6985
ARG A7081
LEU A6961
ILE A7080
1.58A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU A6848
LEU A6883
LEU A6924
ILE A6926
MET A6863
1.73A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU C7078
PHE C6985
ARG C7081
LEU C6961
ILE C7080
1.58A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU C7078
PHE C6985
ARG C7081
LEU C6961
ILE C7080
1.57A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU C7070
SER C7071
LEU C6961
LEU C7060
ILE C7065
1.59A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU C6848
LEU C6883
LEU C6924
ILE C6926
MET C6863
1.74A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU C6924
LEU C6883
SER C6903
PHE C6901
ILE C6926
1.33A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w75 NSP16
(SARS-CoV-2)
5 / 12
LEU C6924
LEU C6883
SER C6903
PHE C6901
ILE C6926
1.30A18.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)
5 / 12
ASP B 302
LEU B 253
SER B 293
HIS B 275
ILE B 300
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)
5 / 12
ASP B 302
LEU B 253
SER B 293
HIS B 275
ILE B 300
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)
5 / 12
ASP A 302
LEU A 253
SER A 293
HIS A 275
ILE A 300
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)
5 / 12
LEU A 152
LEU A 113
PHE A 304
LEU A 172
ILE A 151
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)
5 / 12
LEU B 152
LEU B 113
PHE B 304
LEU B 172
ILE B 151
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)
5 / 12
LEU B 152
LEU B 113
PHE B 304
LEU B 172
ILE B 151
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)
5 / 12
ASP A 302
LEU A 253
SER A 293
HIS A 275
ILE A 300
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wey NSP3
(SARS-CoV-2)
5 / 12
SER A 371
LEU A 216
PHE A 320
LEU A 357
ILE A 222
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A6924
LEU A6883
SER A6903
PHE A6901
ILE A6926
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU C6924
LEU C6883
SER C6903
PHE C6901
ILE C6926
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A6848
LEU A6883
LEU A6924
ILE A6926
MET A6863
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU C7070
SER C7071
LEU C6961
LEU C7060
ILE C7065
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU C7078
PHE C6985
ARG C7081
LEU C6961
ILE C7080
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU C6848
LEU C6883
LEU C6924
ILE C6926
MET C6863
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A7078
PHE A6985
ARG A7081
LEU A6961
ILE A7080
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A6848
LEU A6883
LEU A6924
ILE A6926
MET A6863
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU C6924
LEU C6883
SER C6903
PHE C6901
ILE C6926
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU C7070
SER C7071
LEU C6961
LEU C7060
ILE C7065
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU C7078
PHE C6985
ARG C7081
LEU C6961
ILE C7080
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU C6848
LEU C6883
LEU C6924
ILE C6926
MET C6863
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A7078
PHE A6985
ARG A7081
LEU A6961
ILE A7080
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A7070
SER A7071
LEU A6961
LEU A7060
ILE A7065
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A6924
LEU A6883
SER A6903
PHE A6901
ILE A6926
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)
5 / 12
ASP C  81
SER B 105
LEU C 113
PHE C  53
ILE C  84
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)
5 / 12
ASP C  81
SER B 105
LEU C 113
PHE C  53
ILE C  84
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU A6924
LEU A6883
SER A6903
PHE A6901
ILE A6926
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU A7078
PHE A6985
ARG A7081
LEU A6961
ILE A7080
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU A6848
LEU A6883
LEU A6924
ILE A6926
MET A6863
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU C6924
LEU C6883
SER C6903
PHE C6901
ILE C6926
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU C7070
SER C7071
LEU C6961
LEU C7060
ILE C7065
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU C7070
SER C7071
LEU C6961
LEU C7060
ILE C7065
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU C6848
LEU C6883
LEU C6924
ILE C6926
MET C6863
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU C7078
PHE C6985
ARG C7081
LEU C6961
ILE C7080
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU A6848
LEU A6883
LEU A6924
ILE A6926
MET A6863
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU C6924
LEU C6883
SER C6903
PHE C6901
ILE C6926
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU C7078
PHE C6985
ARG C7081
LEU C6961
ILE C7080
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU A6924
LEU A6883
SER A6903
PHE A6901
ILE A6926
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU C6848
LEU C6883
LEU C6924
ILE C6926
MET C6863
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU A7078
PHE A6985
ARG A7081
LEU A6961
ILE A7080
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wkq NSP16
(SARS-CoV-2)
5 / 12
LEU A7070
SER A7071
LEU A6961
LEU A7060
ILE A7065
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)
5 / 12
ASP B 283
LEU B 246
PHE B 204
ARG B 258
ILE B 281
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)
5 / 12
ASP A 283
LEU A 246
PHE A 204
ARG A 258
ILE A 281
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)
5 / 12
ASP B 283
LEU B 246
ARG B 258
LEU B 255
ILE B 281
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)
5 / 12
ASP B 283
LEU B 246
PHE B 204
ARG B 258
ILE B 281
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)
5 / 12
ASP B 283
LEU B 246
ARG B 258
LEU B 255
ILE B 281
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)
5 / 12
ASP A 283
LEU A 246
ARG A 258
LEU A 255
ILE A 281
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)
5 / 12
SER B 167
LEU B  12
PHE B 116
LEU B 153
ILE B  18
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A6924
LEU A6883
SER A6903
PHE A6901
ILE A6926
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A6848
LEU A6883
LEU A6924
ILE A6926
MET A6863
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A7070
SER A7071
LEU A6961
LEU A7060
ILE A7065
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A6848
LEU A6883
LEU A6924
ILE A6926
MET A6863
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A7078
PHE A6985
ARG A7081
LEU A6961
ILE A7080
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A7078
PHE A6985
ARG A7081
LEU A6961
ILE A7080
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
LEU A6924
LEU A6883
SER A6903
PHE A6901
ILE A6926
1.28A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)
5 / 12
ASP A7067
LEU A7070
SER A7071
LEU A6961
ILE A7065
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wqd NSP7
NSP8
(SARS-CoV-2)
5 / 12
LEU A  13
LEU B  91
MET B  90
SER C   4
LEU B  98
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wqd NSP7
NSP8
(SARS-CoV-2)
5 / 12
LEU C  55
SER A  15
LEU C  40
ILE C  39
MET B  87
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wqd NSP7
NSP8
(SARS-CoV-2)
5 / 12
LEU A  71
LEU A  60
PHE B 147
ARG B 111
ILE B 107
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wqd NSP7
NSP8
(SARS-CoV-2)
5 / 12
LEU A  13
LEU B  91
MET B  90
SER C   4
LEU B  98
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wqd NSP7
NSP8
(SARS-CoV-2)
5 / 12
LEU A  71
LEU A  60
PHE B 147
ARG B 111
ILE B 107
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wrh PEPTIDASE C16
(SARS-CoV-2)
5 / 12
LEU A 152
LEU A 113
SER A 262
PHE A 304
ILE A 151
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wrh PEPTIDASE C16
(SARS-CoV-2)
5 / 12
ASP A 302
LEU A 253
SER A 293
HIS A 275
ILE A 300
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wrh PEPTIDASE C16
(SARS-CoV-2)
5 / 12
LEU A 152
LEU A 113
PHE A 304
LEU A 172
ILE A 151
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wrh PEPTIDASE C16
(SARS-CoV-2)
5 / 12
LEU A 152
LEU A 113
PHE A 304
LEU A 172
ILE A 151
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wrh PEPTIDASE C16
(SARS-CoV-2)
5 / 12
LEU A 152
LEU A 113
SER A 262
PHE A 304
ILE A 151
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6wrh PEPTIDASE C16
(SARS-CoV-2)
5 / 12
ASP A 302
LEU A 253
SER A 293
HIS A 275
ILE A 300
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
SER D   7
LEU E 153
SER E 139
LEU E 164
ILE E  18
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU E 153
LEU E 140
SER D   7
LEU E  10
ILE E  18
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU E 153
LEU E 140
SER D   7
LEU E  10
ILE E  18
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU C 126
SER C 128
LEU C 164
HIS C 138
MET C 171
1.42A
None
None
None
EDO  C 208 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU D 164
LEU D 140
PHE D 116
LEU D 153
ILE D  18
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU E 164
LEU E 140
PHE E 116
LEU E 153
ILE E  18
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU A 164
LEU A 140
PHE A 116
LEU A 153
ILE A  18
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
SER D   7
LEU E 153
SER E 139
LEU E 164
ILE E  18
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU C 126
SER C 128
LEU C 164
HIS C 138
MET C 171
1.44A
None
None
None
EDO  C 208 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU D 164
LEU D 140
PHE D 116
LEU D 153
ILE D  18
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
SER D 167
LEU D  12
PHE D 116
LEU D 153
ILE D  18
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU E 164
LEU E 140
PHE E 116
LEU E 153
ILE E  18
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
SER A 167
LEU A  12
PHE A 116
LEU A 153
ILE A  18
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU E 164
LEU E 140
PHE E 116
LEU E 153
ILE E  18
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
SER D   7
LEU E 153
SER E 139
LEU E 164
ILE E  18
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU C 164
LEU C 140
PHE C 116
LEU C 153
ILE C  18
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
SER D   7
LEU E 153
SER E 139
LEU E 164
ILE E  18
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
SER A 167
LEU A  12
PHE A 116
LEU A 153
ILE A  18
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU A 164
LEU A 140
PHE A 116
LEU A 153
ILE A  18
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
SER A 167
LEU A  12
PHE A 116
LEU A 153
ILE A  18
1.73A
EDO  A 206 ( 4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU A 164
LEU A 140
PHE A 116
LEU A 153
ILE A  18
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU B 126
LEU B 164
PHE A 156
LEU B  12
ILE B  18
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU B 126
LEU B 164
PHE A 156
LEU B  12
ILE B  18
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)
5 / 12
LEU B 164
LEU B 140
PHE B 116
LEU B 153
ILE B  18
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP12
(SARS-CoV-2)
5 / 12
SER A 814
LEU A 869
HIS A 439
ARG A 836
ILE A 837
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP12
(SARS-CoV-2)
5 / 12
ASP A 833
LEU A 862
PHE A 594
ARG A 836
ILE A 837
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP12
(SARS-CoV-2)
5 / 12
SER A 814
LEU A 869
HIS A 439
ARG A 836
ILE A 837
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP7
NSP8
(SARS-CoV-2)
5 / 12
LEU C  28
SER C  10
LEU C  35
ILE D 119
MET C  52
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP12
(SARS-CoV-2)
5 / 12
LEU A 869
SER A 434
HIS A 439
ARG A 836
ILE A 837
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP12
(SARS-CoV-2)
6 / 12
ASP A 126
LEU A 212
LEU A 178
PHE A 165
LEU A 142
ILE A 145
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP12
(SARS-CoV-2)
5 / 12
LEU A 869
HIS A 439
ARG A 836
LEU A 838
ILE A 837
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP12
(SARS-CoV-2)
5 / 12
ASP A 304
LEU A 636
PHE A 283
ARG A 305
ILE A 307
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP12
NSP8
(SARS-CoV-2)
5 / 12
LEU A 271
LEU A 270
SER B 151
LEU B 122
ILE B 119
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP12
(SARS-CoV-2)
5 / 12
LEU A 869
HIS A 439
ARG A 836
LEU A 838
ILE A 837
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP7
(SARS-CoV-2)
5 / 12
ASP C  38
LEU C  55
SER C  15
LEU C  40
ILE C  39
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP12
(SARS-CoV-2)
6 / 12
ASP A 126
LEU A 212
LEU A 178
PHE A 165
LEU A 142
ILE A 145
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP12
(SARS-CoV-2)
5 / 12
LEU A 241
LEU A 245
MET A 463
ARG A 132
LEU A 247
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP12
(SARS-CoV-2)
5 / 12
LEU A 869
SER A 434
HIS A 439
ARG A 836
ILE A 837
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP12
(SARS-CoV-2)
5 / 12
ASP A 833
LEU A 862
PHE A 594
ARG A 836
ILE A 837
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP7
(SARS-CoV-2)
5 / 12
ASP C  38
LEU C  55
SER C  15
LEU C  40
ILE C  39
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7btf NSP12
(SARS-CoV-2)
5 / 12
LEU A 241
LEU A 245
ARG A 132
LEU A 247
ILE A 244
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7bv1 NSP12
NSP8
(SARS-CoV-2)
5 / 12
LEU B 103
MET A 380
LEU B 117
ILE B 120
MET A 666
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7bv1 NSP12
(SARS-CoV-2)
6 / 12
ASP A 126
LEU A 212
LEU A 178
PHE A 165
LEU A 142
ILE A 145
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7bv1 NSP12
(SARS-CoV-2)
5 / 12
LEU A 131
LEU A 127
ARG A 132
LEU A 241
ILE A 244
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7bv1 NSP12
NSP8
(SARS-CoV-2)
5 / 12
LEU B 103
MET A 380
LEU B 117
ILE B 120
MET A 666
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7bv1 NSP12
(SARS-CoV-2)
5 / 12
LEU A 131
LEU A 127
ARG A 132
LEU A 241
ILE A 244
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7bv1 NSP12
(SARS-CoV-2)
6 / 12
ASP A 126
LEU A 212
LEU A 178
PHE A 165
LEU A 142
ILE A 145
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7bv2 NSP12
(SARS-CoV-2)
6 / 12
ASP A 126
LEU A 212
LEU A 178
PHE A 165
LEU A 142
ILE A 145
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7bv2 NSP12
(SARS-CoV-2)
5 / 12
ASP A 304
LEU A 636
PHE A 283
ARG A 305
ILE A 307
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7bv2 NSP12
(SARS-CoV-2)
6 / 12
ASP A 126
LEU A 212
LEU A 178
PHE A 165
LEU A 142
ILE A 145
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7bv2 NSP12
(SARS-CoV-2)
5 / 12
ASP A 304
LEU A 636
PHE A 283
ARG A 305
ILE A 307
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7bv2 NSP12
(SARS-CoV-2)
5 / 12
LEU A 241
LEU A 245
MET A 463
ARG A 132
ILE A 244
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7bv2 NSP12
(SARS-CoV-2)
5 / 12
LEU A 241
LEU A 245
MET A 463
ARG A 132
ILE A 244
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1F_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7bv2 NSP12
(SARS-CoV-2)
5 / 12
LEU A 131
LEU A 127
ARG A 132
LEU A 241
ILE A 244
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4X1G_A_3WFA501_1
(NUCLEAR RECEPTOR
SUBFAMILY 1 GROUP I
MEMBER 2)
7bv2 NSP12
(SARS-CoV-2)
5 / 12
LEU A 131
LEU A 127
ARG A 132
LEU A 241
ILE A 244
1.35A
None